<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /data/rsg/nlp/juanmoo1/bin/grobid-0.6.1/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2020-09-29">29 September 2020</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Haifeng</forename><surname>Zhao</surname></persName>
							<email>zhaohaifeng457@163.com</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yutian</forename><surname>Kan</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xinyuan</forename><surname>Wang</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leiyuan</forename><surname>Chen</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Hematology and Oncology</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peng</forename><surname>Ge</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Department of Laboratory</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhengzi</forename><surname>Qian</surname></persName>
							<email>qianzhengzi123@163.com</email>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Department of Lymphoma</orgName>
								<orgName type="department" key="dep2">Tianjin Clinical Research Center for Cancer</orgName>
								<orgName type="laboratory">Key Laboratory of Cancer Prevention and Therapy</orgName>
								<orgName type="institution" key="instit1">Tianjin Medical University Cancer Institute and Hospital</orgName>
								<orgName type="institution" key="instit2">National Clinical Research Center for Cancer</orgName>
								<address>
									<settlement>Tianjin</settlement>
									<country key="CN">P.R. China</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Genetic polymorphism and transcriptional regulation of CREBBP gene in patient with diffuse large B-cell lymphoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2020-09-29">29 September 2020</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1042/BSR20191162</idno>
					<note type="submission">Received: 23 April 2019 Revised: 17 July 2019 Accepted: 30 July 2019 Accepted Manuscript Online: 31 July 2019</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.1" ident="GROBID" when="2020-10-09T18:38+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<abstract>
				<p>In the present study, we aim to examine the relationship between genetic polymorphism and transcriptional expression of cyclic AMP response element binding protein (CREBBP) and the risk of diffuse large B-cell lymphoma (DLBCL). Two hundred and fifty healthy individuals and 248 DLBCL patients participated in the present study. The CREBBP rs3025684 polymorphism was detected by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The mRNA expression of CREBBP was tested by the real-time quantitative PCR (RT-qPCR). The allele A frequency of CREBBP rs3025684 in DLBCL patients was obviously higher than that of controls (P=0.01). No significant difference was detected between CREBBP rs3025684 polymorphism and clinical characteristics of DLBCL patients when subgrouped according to different parameters. The results demonstrated that the allele A of CREBBP rs3025684 increased the susceptibility to DLBCL (P=0.004), with a worse overall survival (OS) rate (P=0.002), a worse progression-free survival (PFS) rate (P=0.033) and poor prognosis (P=0.003) in DLCBL patients. Furthermore, the expression of CREBBP mRNA was considerably decreased in DLBCL patients as compared with controls (P&lt;0.001), and the expression in patients with GG genotype was up-regulated in comparison with patients with GA and AA genotype (P=0.016 and P=0.001, respectively). However, no statistical differences were found in OS (P=0.201) and PFS (P=0.353) between the lower CREBBP mRNA level subgroup and higher CREBBP mRNA level subgroup. These data suggested that the CREBBP gene may be an important prognostic factor in DLBCL patients and perform an essential function in the development of DLBCL.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Introduction</head><p>Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma with extreme heterogeneity, accounting for 30-40% of newly diagnosed lymphomas <ref type="bibr" target="#b0">[1]</ref>. Although the standard R-CHOP regimen has extremely good therapeutic effect on DLBCL patients, approximately 30-40% of patients show relapse and 10% have refractory disease <ref type="bibr" target="#b1">[2]</ref>. In the past decades, accumulating evidences have shown the genetic, microenvironment, autoimmune diseases and occupational exposure participated in the pathogenesis of DLBCL <ref type="bibr" target="#b2">[3]</ref><ref type="bibr" target="#b3">[4]</ref><ref type="bibr" target="#b4">[5]</ref>. With gene-expression profiling and next-generation sequencing, some common genetic loci are found to enmesh in the lymphomagenesis of DLBCL <ref type="bibr" target="#b5">[6]</ref>. However, the pathogenesis of DLBCL is still not fully understood.</p><p>Single nucleotide polymorphism (SNP) is the most abundant type of genetic variation that occurs at a specific position in the human genome. Accumulating evidence indicated that SNPs have shown the ability to influence the activity and expression of the genes, and affect the pathogenesis and risk of an extensive range of cancer <ref type="bibr" target="#b6">[7]</ref><ref type="bibr" target="#b7">[8]</ref><ref type="bibr" target="#b8">[9]</ref><ref type="bibr" target="#b9">[10]</ref>. Previous studies have demonstrated that SNPs in TP53, XRCC1 and A20 are related to the risk of DLBCL <ref type="bibr" target="#b10">[11]</ref><ref type="bibr" target="#b11">[12]</ref><ref type="bibr" target="#b12">[13]</ref>. Genome-wide association studies have recognized genetic susceptibility locus for DLBCL <ref type="bibr" target="#b13">[14]</ref>. The contribution of SNP in histone-modifying enzymes to DLBCL pathogenesis is a research hotspot.</p><p>Somatic mutations in cyclic AMP response element binding protein (CREBBP) and EP300, and removal or inactivation of the HAT coding domain affect approximately 39% of DLBCL patients <ref type="bibr" target="#b14">[15]</ref>, and are also associated with Rubinstein Tyabi Syndrome (RTS) <ref type="bibr" target="#b15">[16,</ref><ref type="bibr" target="#b16">17]</ref>. CREBBP belongs to the KAT3 family of histone/protein lysine acetyltransferases, which is a highly conserved and universally expressed nuclear phosphoprotein <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b18">19]</ref>. CREBBP inactivation expedites GC-derived pathogenesis of lymphoma <ref type="bibr" target="#b19">[20]</ref>. Down-regulation of CREBBP is related to worse overall survival (OS) rate in pediatric acute lymphoblastic leukemia and may affect the response to chemotherapy <ref type="bibr" target="#b20">[21]</ref>. Crebbp +/− mice had blemish in the development of B-cell lymphoid and an increased incidence of hematopoietic malignancy <ref type="bibr" target="#b21">[22]</ref>. The rs3025684 (A/G) is an SNP of CREBBP located in intron 21. This SNP was shown to be a possible risk factor for developing autism in the Netherlands, U.K. and Denmark, as well as among Bengali-Hindus <ref type="bibr" target="#b22">[23,</ref><ref type="bibr" target="#b23">24]</ref>.</p><p>However, the status of CREBBP rs3025684 SNP and the gene expression in DLBCL in a Chinese Han population is not completely understood. It was hypothesized that CREBBP rs3025684 polymorphism and expression may be related to the susceptibility and pathogenesis of DLBCL, and the results found that it may be a prognostic factor for DLBCL patients.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Subjects</head><p>The present study recruited 250 healthy individuals and 248 DLBCL patients, diagnosed according to the World Health Organization classification <ref type="bibr" target="#b24">[25]</ref> at Tianjin Medical University Cancer Institute and Hospital from 2011 to 2013. Peripheral blood and lymphoid specimens were collected before initial therapy. All participants signed the informed consent, and the approval of the study was obtained from the Tianjin Cancer Institute Institutional Review Board. The clinical and pathological characteristics of the patients and controls are presented in <ref type="table" target="#tab_0">Table 1</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Extraction of DNA and genotyping of CREBBP rs3025684</head><p>The TIANamp genomic DNA kit (TIANGEN Biotech, Beijing, China) was used to extract the genomic DNA according to the manufacturer's protocol. Genotypes were analyzed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). The reaction system contained 60 ng DNA template, 2 μl of each primer, 25 μl Premix Taq (Takara, Dalian, China) and sterilized water up to 50 μl. The PCR protocol was as follows: initial denaturation at 94 • C for 5 min, followed by 30 cycles of denaturation at 94 • C for 30 s, annealing at 58 • C for 30 s, extension at 72 • C for 30 s, followed by 72 • C for 7 min. The primers for rs3025684 were: forward 5 -AGGGGAAACAACTCACCCTG-3 and reverse 5 -CTGGTCTTGTGGTTCCGTGT-3 . The PCR product was digested by MnlI (New England Biolabs, Beverly, MA) and analyzed by gel electrophoresis on 2.5% agarose gels. Randomly selected DNA samples were detected by direct sequencing to verify the results (Supplementary <ref type="figure" target="#fig_0">Figure S1</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Isolation of RNA and reverse-transcription quantitative PCR</head><p>Total RNA was isolated using TRIzol reagent (Invitrogen). We normalized the levels of expression of CREBBP relative to glyceraldehyde phosphate dehydrogenase (GAPDH), and 2 − C t indicated the quantification of gene expression. The primers for CREBBP were: forward 5 -CGGCTCTAGTATCAACCCAGG-3 and reverse 5 -TTTTGTGCTT GCGGATTCAGT-3 . The primers for 0:italic GAPDH /0:italic were:forward5 -CCACATCGCTCAGACACCAT-3 andreverse5 -CCAGGCGCCCAATACG-3 .</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistical analysis</head><p>A goodness-of-fit Chi-square test was used to analyze the Hardy-Weinberg equilibrium. The Chi-square test was used to detect the allelic frequency and genotypic distribution in all subjects. We estimated the relationship between CREBBP rs3025684 and the susceptibility to DLBCL by unconditional logistic regression. The prognostic factors were explored by univariate Cox regression analysis. The CREBBP mRNA expression levels were investigated by the independent Student's t test. The survival curves were computed by Kaplan-Meier method with log-rank tests. All the statistical analyses mentioned above were executed by IBM SPSS Statistics version 20.0. P&lt;0.05 was considered to be statistically significant. The false-positive report probability (FPRP) was calculated as previously described <ref type="bibr" target="#b25">[26]</ref>, we set an FPRP value of 0.2 and assigned a prior probability of 0.1. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Characteristics of study subjects</head><p>The genotypic distributions in both patients and controls were under the Hardy-Weinberg equilibrium (P&gt;0.05).</p><p>The genotypic distribution and allelic frequencies showed significant difference between the DLBCL patients and healthy individuals for CREBBP rs3025684 (P=0.021 and P=0.013, respectively, shown in <ref type="table" target="#tab_1">Table 2</ref>). Furthermore, the association between the genotype and the clinical parameters of DLBCL patients was explored, which showed no statistical differences as shown in <ref type="table" target="#tab_2">Table 3</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Relationship between the CREBBP rs3025684 and the susceptibility to DLBCL</head><p>The GA genotype was correlated with the risk of DLBCL (odds ratio (OR) = 1.692, 95% confidence interval (95% CI) = 1.170-2.446, P=0.005) <ref type="table" target="#tab_3">(Table 4</ref>). However, the AA genotype displayed a slightly increased susceptibility to DLBCL with no statistical significance (OR = 1.620, 95% CI = 0.710-3.696, P=0.252, P=0.252) ( <ref type="table" target="#tab_3">Table 4</ref>). The combined AA and GA genotype was significantly related to increased susceptibility to DLBCL (OR = 1.684, 95% CI = 1.179-2.404, P=0.004) ( <ref type="table" target="#tab_3">Table 4)</ref>. The results for dominant and recessive models are shown in <ref type="table" target="#tab_3">Table 4</ref>. As no statistical significance was shown in the dominant model, we did not calculate the FPRP values and statistical power for the dominant model. Positive association was observed in the recessive model and GA genotype as their FPRP value was less than 0.2 (shown in <ref type="table" target="#tab_3">Table 4</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival analysis of DLBCL patients according to the CREBBP rs3025684</head><p>The survival analysis of all 248 DLBCL patients showed that the patients with genotype GA/AA (P=0.006, <ref type="figure" target="#fig_0">Figure  1A</ref>) and the combined GA and AA group (P=0.002, <ref type="figure" target="#fig_0">Figure 1B</ref>) had a worse OS than patients with GG genotype. Furthermore, the patients with GA/AA genotype had a worse progression-free survival (PFS) in comparison with the GG patients with no statistical significance (P=0.058, <ref type="figure" target="#fig_0">Figure 1C)</ref>, however, the combined GA and AA group showed worse PFS rate compared with the GG group with statistically significant (P=0.033, <ref type="figure" target="#fig_0">Figure 1D</ref>). Furthermore, it was also indicated that patients with A allele showed poor prognosis (P=0.003, HR = 1.944, 95% CI = 1.247-3.029).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Analysis of the CREBBP mRNA expression levels</head><p>CREBBP expression was detected in 63 patients and 32 controls. The results showed that the CREBBP expression was remarkably down-regulated in patients as compared with controls (P&lt;0.001, <ref type="figure" target="#fig_1">Figure 2A</ref>). The CREBBP expression of patients with GG genotype was down-regulated as compared with the patients with GA and AA genotype (P=0.016 and 0.001, respectively, <ref type="figure" target="#fig_1">Figure 2B</ref>). However, no significant difference was detected between the GA and AA subgroups (P=0.134, <ref type="figure" target="#fig_1">Figure 2B</ref>). The CREBBP expression was down-regulated in the GA/AA subgroup as compared with the GG subgroup (P=0.002, <ref type="figure" target="#fig_1">Figure 2C</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Survival analysis based on the CREBBP mRNA levels of DLBCL patients</head><p>Based on the median of CREBBP mRNA expression value, 63 DLBCL patients were partitioned into two subgroups, the low CREBBP expression subgroup and the high CREBBP expression subgroup. The results indicated no significant differences between the patients with lower CREBBP mRNA level and those with high CREBBP mRNA level in OS (P=0.201, <ref type="figure" target="#fig_2">Figure 3A)</ref> and PFS (P=0.353, <ref type="figure" target="#fig_2">Figure 3B</ref>).</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p>DLBCL is an example of a translocation-based cancer, in which key genes are dysregulated by active lineage-specific promoters or enhancers due to characteristic equilibrium translocations <ref type="bibr" target="#b5">[6]</ref>. The evolution of DLBCL was a multi-step procedure that requires the cumulation of multiple genetic pathological changes <ref type="bibr" target="#b13">[14,</ref><ref type="bibr" target="#b26">27]</ref>. By the modern genome-wide   molecular analysis, an abundance of altered cellular pathways that perform vital functions in the development of DLBCL and the sensitivity of cancer cells to therapy was detected. However, the notable heterogeneity of this disease partly limits the effective treatment. Therefore, it is necessary to seek ameliorated special biomarkers, permitting the devising of more efficient and accurate medical methods to specific cancer-causing addictions. CREBBP, one of the most frequently mutated genes in DLBCL <ref type="bibr" target="#b14">[15,</ref><ref type="bibr" target="#b27">[28]</ref><ref type="bibr" target="#b28">[29]</ref><ref type="bibr" target="#b29">[30]</ref>, acts as a tumor repressor of GC-derived pathogenesis of lymphoma <ref type="bibr" target="#b30">[31]</ref>. Most of the CREBBP-binding regions in GC B cells displayed characteristics of transcriptionally active (or suspended) enhancers <ref type="bibr" target="#b31">[32]</ref>, which control the cell type-specific transcription <ref type="bibr" target="#b32">[33]</ref>. CREBBP acetylates H3K27 on the promoter or enhancer sequence of the BCL6 target genes, promoting transcription to counteracting the inhibition of BCL6, which leads to the opposition of proto-oncogene activity of BCL6 <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b30">31]</ref>. Therefore, CREBBP may be considered as a tumor therapeutic target in DLBCL patients.</p><p>Gene expression-based categorization of DLBCL has been established <ref type="bibr" target="#b33">[34,</ref><ref type="bibr" target="#b34">35]</ref>, and the relevance to prognosis has been illustrated <ref type="bibr" target="#b35">[36]</ref>. It has been demonstrated that certain genetic defects and distinct signal transduction pathways occur in specific subtypes <ref type="bibr" target="#b36">[37,</ref><ref type="bibr" target="#b37">38]</ref>. In this study, the association between CREBBP rs3025684 polymorphism and its expression with the susceptibility and survival of DLBCL patients was investigated. The results showed that the A allele carriers were related to increased risk of DLBCL and had worse OS rate and PFS rate. Hence, CREBBP rs3025684 polymorphism may be used as a hallmark for the prediction of risk and prognosis of DLBCL.</p><p>In East Asians, the frequency of A allele of CREBBP rs3025684 was reported to be 19.3% in the HapMap Project. However, the present study showed that the frequency of allele A in controls and DLBCL patients was 21.60 and 28.43%, respectively. This difference in allele frequency may owe to the risk effects of allele A and the small sample The expression of CREBBP mRNA in DLBCL patients with GG genotype was significantly up-regulated than those with GA and AA genotypes (P=0.016 and 0.001, respectively). (C) The expression of CREBBP mRNA in DLBCL patients with GA/AA genotype was significantly down-regulated than those with GG genotype (P=0.002). size. In the recessive model, the positive association between the risk of DLBCL and CREBBP rs3025684 was observed. However, the statistical power was only 0.5, which may be a result of the small simple size.</p><p>The CREBBP/EP300 complex participates in numerous life events, such as cell growth, proliferation, apoptosis, metabolism and oncogenesis <ref type="bibr" target="#b17">[18,</ref><ref type="bibr" target="#b38">39,</ref><ref type="bibr" target="#b39">40]</ref>. CREBBP/EP300 complex also targets many transcriptional factors significantly related to the development of B-cell lymphoma and immune response, such as p53 and c-MYC <ref type="bibr" target="#b40">[41]</ref><ref type="bibr" target="#b41">[42]</ref><ref type="bibr" target="#b42">[43]</ref>. HAT activity is related to the survival rate of patients with B-cell lymphoma <ref type="bibr" target="#b30">[31,</ref><ref type="bibr" target="#b43">44]</ref>. Furthermore, HAT mutations likely predict treatment efficiency in epigenetically targeted therapy, such as the HDAC3 inhibitors <ref type="bibr" target="#b19">[20,</ref><ref type="bibr" target="#b44">45]</ref>. The present study indicated that the expression of CREBBP was notably down-regulated in patients as compared with the controls, and was especially down-regulated in the GA/AA genotype subgroup, indicating that CREBBP may be used as a therapeutic target for DLBCL.</p><p>In conclusion, the polymorphism and expression of CREBBP gene may play a vital role as a genetic risk factor and poor prognostic factor among DLBCL Chinese Han patients, indicating that CREBBP could be used for the prognosis and treatment of DLBCL. Additional studies with larger sample sizes are necessary to verify the results and further functional analyses are warranted to explore the lymphoma biology.</p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Figure 1 .</head><label>1</label><figDesc>Survival analyses of DLBCL patients under the genotype of CREBBP rs3025684 (A) OS analysis compared among the GG, GA and AA subgroups (P=0.006). (B) OS analysis compared between the GG subgroup and the combined GA/AA subgroup (P=0.002). (C) PFS analysis compared among the GG, GA and AA subgroups (P=0.058). (D) PFS analysis compared between the GG subgroup and the combined GA/AA subgroup (P=0.033). A check mark indicates that the data is censored.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head>Figure 2 .</head><label>2</label><figDesc>The expression of CREBBP mRNA in DLBCL patients (A) The expression of CREBBP mRNA in DLBCL patients was down-regulated as compared with the controls (P&lt;0.001). (B)</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_2"><head>Figure 3 .</head><label>3</label><figDesc>Survival analyses of DLBCL patients according to CREBBP mRNA expression (A) The OS analysis indicated no significant differences between lower CREBBP subgroup and high CREBBP subgroup (P=0.201). (B) The PFS analysis indicated no significant differences between the lower CREBBP subgroup and high CREBBP subgroup (P=0.353). A check mark indicates that the data is censored.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 Clinical characteristics of DLBCL patients</head><label>1</label><figDesc>CR, complete response; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; LDH, lactate dehydrogenase; PR, partial response; β2-MG, β2 macroglobulin.</figDesc><table><row><cell>Characteristics</cell><cell>Number (n=248) n (%)</cell><cell>Control (n=250) n (%)</cell></row><row><cell>Gender</cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>112 (45.16)</cell><cell>109 (43.60)</cell></row><row><cell>Female</cell><cell>136 (54.84)</cell><cell>141 (56.40)</cell></row><row><cell>Age</cell><cell></cell><cell></cell></row><row><cell>≤60</cell><cell>165 (66.53)</cell><cell>184 (73.60)</cell></row><row><cell>&gt;60</cell><cell>83 (33.47)</cell><cell>66 (26.40)</cell></row><row><cell>Subtype</cell><cell></cell><cell></cell></row><row><cell>GCB</cell><cell>75 (30.24)</cell><cell></cell></row><row><cell>nGCB</cell><cell>173 (69.76)</cell><cell></cell></row><row><cell>Ann-arbor stage</cell><cell></cell><cell></cell></row><row><cell>I-II</cell><cell>152 (61.29)</cell><cell></cell></row><row><cell>III-IV</cell><cell>96 (38.71)</cell><cell></cell></row><row><cell>IPI score</cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>133 (53.63)</cell><cell></cell></row><row><cell>2-5</cell><cell>115 (46.37)</cell><cell></cell></row><row><cell>ECOG</cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>230 (92.74)</cell><cell></cell></row><row><cell>2-5</cell><cell>18 (7.26)</cell><cell></cell></row><row><cell>B symptom</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>79 (31.85)</cell><cell></cell></row><row><cell>−</cell><cell>169 (68.15)</cell><cell></cell></row><row><cell>Extra nodal sites</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>156 (62.90)</cell><cell></cell></row><row><cell>−</cell><cell>92 (37.10)</cell><cell></cell></row><row><cell>Bone marrow involvement</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>21 (8.47)</cell><cell></cell></row><row><cell>−</cell><cell>227 (91.53)</cell><cell></cell></row><row><cell>HBV infection</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>74 (29.84)</cell><cell></cell></row><row><cell>−</cell><cell>174 (70.16)</cell><cell></cell></row><row><cell>Bulky tumor (&gt;10 cm)</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>55 (22.18)</cell><cell></cell></row><row><cell>−</cell><cell>193 (77.82)</cell><cell></cell></row><row><cell>Elevated LDH</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>98 (39.52)</cell><cell></cell></row><row><cell>−</cell><cell>150 (60.48)</cell><cell></cell></row><row><cell>Elevated β2-MG</cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>86 (34.68)</cell><cell></cell></row><row><cell>−</cell><cell>162 (65.32)</cell><cell></cell></row><row><cell>KI-67</cell><cell></cell><cell></cell></row><row><cell>≤75%</cell><cell>93 (37.50)</cell><cell></cell></row><row><cell>&gt;75%</cell><cell>155 (62.50)</cell><cell></cell></row><row><cell>Source</cell><cell></cell><cell></cell></row><row><cell>Gastrointestinal</cell><cell>116 (46.77)</cell><cell></cell></row><row><cell>Others</cell><cell>132 (53.23)</cell><cell></cell></row><row><cell>Response rate</cell><cell></cell><cell></cell></row><row><cell>PR+CR</cell><cell>215 (86.69)</cell><cell></cell></row><row><cell>Abbreviations:</cell><cell></cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 Genotype distribution and allele frequencies of CREBBP rs3025684 polymorphism in DLBCL patients and the controls</head><label>2</label><figDesc></figDesc><table><row><cell></cell><cell>Control (n=250) n (%)</cell><cell>DLBCL patients (n=248) n (%)</cell><cell>P</cell></row><row><cell>Genotype frequency</cell><cell></cell><cell></cell><cell></cell></row><row><cell>GG</cell><cell>153 (61.20)</cell><cell>121 (48.79)</cell><cell>0.021</cell></row><row><cell>GA</cell><cell>86 (34.40)</cell><cell>113 (45.56)</cell><cell></cell></row><row><cell>AA</cell><cell>11 (4.40)</cell><cell>14 (5.65)</cell><cell></cell></row><row><cell>Allele frequency</cell><cell></cell><cell></cell><cell></cell></row><row><cell>G</cell><cell>392 (78.40)</cell><cell>355 (71.57)</cell><cell>0.013</cell></row><row><cell>A</cell><cell>108 (21.60)</cell><cell>141 (28.43)</cell><cell></cell></row></table><note></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_2"><head>Table 3 Characteristics of DLBCL patients and their association with CREBBP rs3025684</head><label>3</label><figDesc></figDesc><table><row><cell>Characteristics</cell><cell>Number</cell><cell>Genotype</cell><cell></cell><cell>P</cell></row><row><cell></cell><cell>(n=248) n (%)</cell><cell>GA+AA, n (%)</cell><cell>GG, n (%)</cell><cell></cell></row><row><cell>Gender</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Male</cell><cell>112 (45.16)</cell><cell>61 (24.60)</cell><cell>51 (20.56)</cell><cell>0.352</cell></row><row><cell>Female</cell><cell>136 (54.84)</cell><cell>66 (26.61)</cell><cell>70 (28.23)</cell><cell></cell></row><row><cell>Age</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤60</cell><cell>165 (66.53)</cell><cell>87 (35.08)</cell><cell>78 (31.45)</cell><cell>0.500</cell></row><row><cell>&gt;60</cell><cell>83 (33.47)</cell><cell>40 (16.13)</cell><cell>43 (17.34)</cell><cell></cell></row><row><cell>Subtype</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GCB</cell><cell>75 (30.24)</cell><cell>38 (15.32)</cell><cell>37 (14.92)</cell><cell>0.910</cell></row><row><cell>nGCB</cell><cell>173 (69.76)</cell><cell>89 (35.89)</cell><cell>84 (33.87)</cell><cell></cell></row><row><cell>Ann-arbor stage</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>I-II</cell><cell>152 (61.29)</cell><cell>73 (29.44)</cell><cell>79 (31.85)</cell><cell>0.207</cell></row><row><cell>III-IV</cell><cell>96 (38.71)</cell><cell>54 (21.77)</cell><cell>42 (16.94)</cell><cell></cell></row><row><cell>IPI score</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>133 (53.63)</cell><cell>62 (25.00)</cell><cell>71 (28.63)</cell><cell>0.120</cell></row><row><cell>2-5</cell><cell>115 (46.37)</cell><cell>65 (26.21)</cell><cell>50 (20.16)</cell><cell></cell></row><row><cell>ECOG</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>0-1</cell><cell>230 (92.74)</cell><cell>114 (45.97)</cell><cell>116 (46.77)</cell><cell>0.064</cell></row><row><cell>2-5</cell><cell>18 (7.26)</cell><cell>13 (5.24)</cell><cell>5 (2.02)</cell><cell></cell></row><row><cell>B symptom</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>79 (31.85)</cell><cell>43 (17.34)</cell><cell>36 (14.52)</cell><cell>0.488</cell></row><row><cell>−</cell><cell>169 (68.15)</cell><cell>84 (33.87)</cell><cell>85 (34.27)</cell><cell></cell></row><row><cell>Bone marrow involvement</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>21 (8.47)</cell><cell>11 (4.44)</cell><cell>10 (4.03)</cell><cell>0.911</cell></row><row><cell>−</cell><cell>227 (91.53)</cell><cell>116 (46.77)</cell><cell>111 (44.76)</cell><cell></cell></row><row><cell>HBV infection</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>74 (29.84)</cell><cell>39 (15.73)</cell><cell>35 (14.11)</cell><cell>0.759</cell></row><row><cell>−</cell><cell>174 (70.16)</cell><cell>88 (35.48)</cell><cell>86 (34.68)</cell><cell></cell></row><row><cell>Bulky tumor (&gt;10 cm)</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>55 (22.18)</cell><cell>31 (12.50)</cell><cell>24 (9.68)</cell><cell>0.386</cell></row><row><cell>−</cell><cell>193 (77.82)</cell><cell>96 (38.71)</cell><cell>97 (39.11)</cell><cell></cell></row><row><cell>Elevated LDH</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>98 (39.52)</cell><cell>57 (22.98)</cell><cell>41 (16.53)</cell><cell>0.077</cell></row><row><cell>−</cell><cell>150 (60.48)</cell><cell>70 (28.23)</cell><cell>80 (32.26)</cell><cell></cell></row><row><cell>Elevated β2-MG</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>+</cell><cell>86 (34.68)</cell><cell>41 (16.53)</cell><cell>43 (17.34)</cell><cell>0.588</cell></row><row><cell>−</cell><cell>162 (65.32)</cell><cell>86 (34.68)</cell><cell>78 (31.45)</cell><cell></cell></row><row><cell>KI-67</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>≤75%</cell><cell>93 (37.50)</cell><cell>50 (20.16)</cell><cell>43 (17.34)</cell><cell>0.533</cell></row><row><cell>&gt;75%</cell><cell>155 (62.50)</cell><cell>77 (31.05)</cell><cell>78 (31.45)</cell><cell></cell></row><row><cell>Source</cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Gastrointestinal</cell><cell>116 (46.77)</cell><cell>55 (22.18)</cell><cell>61 (24.60)</cell><cell>0.262</cell></row><row><cell>Others</cell><cell>132 (53.23)</cell><cell>72 (29.03)</cell><cell>60 (24.19)</cell><cell></cell></row></table><note>Abbreviations: LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; IPI, International Prognostic Index; β2-MG, β2 macroglobulin.</note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_3"><head>Table 4 Association between CREBBP rs3025684 polymorphism and the risk of DLBCL</head><label>4</label><figDesc></figDesc><table><row><cell></cell><cell></cell><cell></cell><cell>Statistical</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Genotype</cell><cell>OR (95% CI)</cell><cell>P</cell><cell>power</cell><cell></cell><cell></cell><cell cols="2">Prior probability</cell><cell></cell></row><row><cell></cell><cell></cell><cell></cell><cell></cell><cell>0.25</cell><cell>0.1</cell><cell>0.01</cell><cell>0.001</cell><cell>0.0001</cell></row><row><cell>AA vs. GG</cell><cell>1.620 (0.710-3.696)</cell><cell>0.252</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>GA vs.GG</cell><cell>1.692 (1.170-2.446)</cell><cell>0.005</cell><cell>0.500</cell><cell>0.030</cell><cell>0.085</cell><cell>0.505</cell><cell>0.0912</cell><cell>0.990</cell></row><row><cell>GA/AA vs. GG</cell><cell>1.684 (1.179-2.404)</cell><cell>0.004</cell><cell>0.500</cell><cell>0.024</cell><cell>0.069</cell><cell>0.449</cell><cell>0.891</cell><cell>0.988</cell></row><row><cell>GA/GG vs. AA</cell><cell>0.769 (0.342-1.729)</cell><cell>0.526</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).Downloaded from http://portlandpress.com/bioscirep/article-pdf/39/8/BSR20191162/847142/bsr-2019-1162.pdf by UK user on 29 September 2020</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">© 2019 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).</note>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Downloaded from http://portlandpress.com/bioscirep/article-pdf/39/8/BSR20191162/847142/bsr-2019-1162.pdf by UK user on 29 September 2020</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Competing Interests</head><p>The authors declare that there are no competing interests associated with the manuscript. </p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Abbreviations</head><p>CREBBP, cyclic AMP response element binding protein; DLBCL, diffuse large B-cell lymphoma; FPRP, false-positive report probability; GAPDH, glyceraldehyde phosphate dehydrogenase; HAT, histone acetyltransferase; HDAC3, histone deacetylase 3; HR, hazard ratio; OR, odds ratio; OS, overall survival; PFS, progression-free survival; SNP, single nucleotide polymorphism; 95% CI, 95% confidence interval.</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Aggressive lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Staudt</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMra0807082</idno>
		<ptr target="https://doi.org/10.1056/NEJMra0807082" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">362</biblScope>
			<biblScope unit="page" from="1417" to="1429" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d&apos;Etudes des Lymphomes de l&apos;Adulte</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Coiffier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Thieblemont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Van Den Neste</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lepeu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Plantier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Castaigne</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2010-03-276246</idno>
		<ptr target="https://doi.org/10.1182/blood-2010-03-276246" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">116</biblScope>
			<biblScope unit="page" from="2040" to="2045" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">M</forename><surname>Morton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Slager</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Cerhan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">M</forename><surname>Vajdic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">F</forename><surname>Skibola</surname></persName>
		</author>
		<idno type="DOI">10.1093/jncimonographs/lgu013</idno>
		<ptr target="https://doi.org/10.1093/jncimonographs/lgu013" />
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer Inst. Monogr</title>
		<imprint>
			<biblScope unit="page" from="130" to="144" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Familial predisposition and genetic risk factors for lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Cerhan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">L</forename><surname>Slager</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2015-04-537498</idno>
		<ptr target="https://doi.org/10.1182/blood-2015-04-537498" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">126</biblScope>
			<biblScope unit="page" from="2265" to="2273" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">The tumour microenvironment in B cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Scott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrc3774</idno>
		<ptr target="https://doi.org/10.1038/nrc3774" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Cancer</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="517" to="534" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">O</forename><surname>Armitage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Lunning</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Cavalli</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0140-6736(16)32407-2</idno>
		<ptr target="https://doi.org/10.1016/S0140-6736" />
	</analytic>
	<monogr>
		<title level="j">Lancet</title>
		<imprint>
			<biblScope unit="volume">390</biblScope>
			<biblScope unit="issue">16</biblScope>
			<biblScope unit="page" from="32407" to="32409" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Single nucleotide polymorphism in SMAD7 and CHI3L1 and colorectal cancer risk</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Abd</forename><surname>El-Fattah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Sadik</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">A H</forename><surname>Shaker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><forename type="middle">G</forename></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mohamed</forename><surname>Kamal</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename></persName>
		</author>
		<idno type="DOI">10.1155/2018/9853192</idno>
		<ptr target="https://doi.org/10.1155/2018/9853192" />
	</analytic>
	<monogr>
		<title level="j">Mediators Inflamm</title>
		<imprint>
			<biblScope unit="volume">9853192</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Association of miRNA biosynthesis genes DROSHA and DGCR8 polymorphisms with cancer susceptibility: a systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Wen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><surname>Lv</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Sun</surname></persName>
		</author>
		<idno type="DOI">10.1042/BSR20180072</idno>
		<ptr target="https://doi.org/10.1042/BSR20180072" />
	</analytic>
	<monogr>
		<title level="j">Biosci. Rep</title>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Fang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Chen</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.lungcan.2017.08.026</idno>
		<ptr target="https://doi.org/10.1016/j.lungcan.2017.08.026" />
	</analytic>
	<monogr>
		<title level="j">Lung Cancer</title>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="page" from="18" to="29" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Interaction between TP53 and XRCC1 increases susceptibility to cervical cancer development: a case control study</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">C</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><forename type="middle">F</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">C</forename><surname>Su</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12885-018-5149-0</idno>
		<ptr target="https://doi.org/10.1186/s12885-018-5149-0" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<date type="published" when="2019" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Genetic polymorphisms in the DNA repair gene, XRCC1 associate with non-Hodgkin lymphoma susceptibility: a systematic review and meta-analysis</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Li</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ejmg.2015.12.011</idno>
		<ptr target="https://doi.org/10.1016/j.ejmg.2015.12.011" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Med. Genet</title>
		<imprint>
			<biblScope unit="volume">59</biblScope>
			<biblScope unit="page" from="91" to="103" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Higher incidence of the SNP Met 788 Ile in the coding region of A20 in diffuse large B cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Wenzl</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Hofer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Troppan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Lassnig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Steinbauer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Wiltgen</surname></persName>
		</author>
		<idno type="DOI">10.1007/s13277-015-4322-1</idno>
		<ptr target="https://doi.org/10.1007/s13277-015-4322-1" />
	</analytic>
	<monogr>
		<title level="j">Tumour Biol</title>
		<imprint>
			<biblScope unit="volume">37</biblScope>
			<biblScope unit="page" from="4785" to="4789" />
			<date type="published" when="2016" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">TP53 Arg72 as a favorable prognostic factor for Chinese diffuse large B-cell lymphoma patients treated with CHOP</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Ding</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Mi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Ping</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><surname>Jin</surname></persName>
		</author>
		<idno type="DOI">10.1186/s12885-017-3760-0</idno>
		<ptr target="https://doi.org/10.1186/s12885-017-3760-0" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<imprint>
			<biblScope unit="volume">17</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Genome-wide association study identifies multiple susceptibility loci for diffuse large B cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">R</forename><surname>Cerhan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">I</forename><surname>Berndt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Vijai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Ghesquieres</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Mckay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng.3105</idno>
		<ptr target="https://doi.org/10.1038/ng.3105" />
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">46</biblScope>
			<biblScope unit="page" from="1233" to="1238" />
			<date type="published" when="2014" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Inactivating mutations of acetyltransferase genes in B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Pasqualucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Dominguez-Sola</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chiarenza</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Grunn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Trifonov</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature09730</idno>
		<ptr target="https://doi.org/10.1038/nature09730" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">471</biblScope>
			<biblScope unit="page" from="189" to="195" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">DNA sequencing of CREBBP demonstrates mutations in 56% of patients with Rubinstein-Taybi syndrome (RSTS) and in another patient with incomplete RSTS</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Bartsch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Schmidt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Richter</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Morlot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Seemanova</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wiebe</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00439-005-1331-y</idno>
		<ptr target="https://doi.org/10.1007/s00439-005-1331-y" />
	</analytic>
	<monogr>
		<title level="j">Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">117</biblScope>
			<biblScope unit="page" from="485" to="493" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Spectrum of CREBBP gene dosage anomalies in Rubinstein-Taybi syndrome patients</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Stef</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Simon</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Mardirossian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Delrue</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Burgelin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Hubert</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.ejhg.5201847</idno>
		<ptr target="https://doi.org/10.1038/sj.ejhg.5201847" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="page" from="843" to="847" />
			<date type="published" when="2007" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">CBP/p300 in cell growth, transformation, and development</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Goodman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Smolik</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1553" to="1577" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">CBP and p300: HATs for different occasions</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Kalkhoven</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bcp.2004.03.045</idno>
		<ptr target="https://doi.org/10.1016/j.bcp.2004.03.045" />
	</analytic>
	<monogr>
		<title level="j">Biochem. Pharmacol</title>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="page" from="1145" to="1155" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">CREBBP inactivation promotes the development of HDAC3-dependent lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ortega-Molina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Geng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">Y</forename><surname>Ying</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Hatzi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Parsa</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-16-0975</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-16-0975" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="38" to="53" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Low CREBBP expression is associated with adverse long-term outcomes in paediatric acute lymphoblastic leukaemia</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">G</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">X</forename><forename type="middle">X</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Cui</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Z</forename><forename type="middle">X</forename><surname>Yue</surname></persName>
		</author>
		<idno type="DOI">10.1111/ejh.12897</idno>
		<ptr target="https://doi.org/10.1111/ejh.12897" />
	</analytic>
	<monogr>
		<title level="j">Eur. J. Haematol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="page" from="150" to="159" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">L</forename><surname>Kung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">I</forename><surname>Rebel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">T</forename><surname>Bronson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><forename type="middle">E</forename><surname>Ch'ng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Sieff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">M</forename><surname>Livingston</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Genes Dev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="272" to="277" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Candidate-gene screening and association analysis at the autism-susceptibility locus on chromosome 16p: evidence of association at GRIN2A and ABAT</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Barnby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Abbott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Sykes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Morris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">E</forename><surname>Weeks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Mott</surname></persName>
		</author>
		<idno type="DOI">10.1086/430454</idno>
		<ptr target="https://doi.org/10.1086/430454" />
	</analytic>
	<monogr>
		<title level="j">Am. J. Hum. Genet</title>
		<imprint>
			<biblScope unit="volume">76</biblScope>
			<biblScope unit="page" from="950" to="966" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">A polymorphism of the CREB binding protein (CREBBP) gene is a risk factor for addiction</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Deb</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Chakraborty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Mukhopadhyay</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Das</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.brainres.2011.05.048</idno>
		<ptr target="https://doi.org/10.1016/j.brainres.2011.05.048" />
	</analytic>
	<monogr>
		<title level="j">Brain Res</title>
		<imprint>
			<biblScope unit="volume">1406</biblScope>
			<biblScope unit="page" from="59" to="64" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">WHO non-Hodgkin&apos;s lymphoma classification by criterion-based report review followed by targeted pathology review: an effective strategy for epidemiology studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">J</forename><surname>Turner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Hughes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Kricker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Milliken</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Grulich</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Kaldor</surname></persName>
		</author>
		<idno type="DOI">10.1158/1055-9965.EPI-05-0358</idno>
		<ptr target="https://doi.org/10.1158/1055-9965.EPI-05-0358" />
	</analytic>
	<monogr>
		<title level="j">Cancer Epidemiol. Biomarkers Prev</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="2213" to="2219" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Assessing the probability that a positive report is false: an approach for molecular epidemiology studies</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Wacholder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Chanock</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Garcia-Closas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>El Ghormli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><surname>Rothman</surname></persName>
		</author>
		<idno type="DOI">10.1093/jnci/djh075</idno>
		<ptr target="https://doi.org/10.1093/jnci/djh075" />
	</analytic>
	<monogr>
		<title level="j">J. Natl. Cancer Inst</title>
		<imprint>
			<biblScope unit="volume">96</biblScope>
			<biblScope unit="page" from="434" to="442" />
			<date type="published" when="2004" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">Genetics and pathogenesis of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><forename type="middle">W</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">W</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">A</forename><surname>Johnson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">D</forename><surname>Phelan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Q</forename><surname>Wang</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa1801445</idno>
		<ptr target="https://doi.org/10.1056/NEJMoa1801445" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">378</biblScope>
			<biblScope unit="page" from="1396" to="1407" />
			<date type="published" when="2018" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">G</forename><surname>Lohr</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Stojanov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">S</forename><surname>Lawrence</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Auclair</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><surname>Chapuy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Sougnez</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.1121343109</idno>
		<ptr target="https://doi.org/10.1073/pnas.1121343109" />
	</analytic>
	<monogr>
		<title level="j">Proc. Natl. Acad. Sci. U.S.A</title>
		<imprint>
			<biblScope unit="volume">109</biblScope>
			<biblScope unit="page" from="3879" to="3884" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Morin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mendez-Lago</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">J</forename><surname>Mungall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Goya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">L</forename><surname>Mungall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">D</forename><surname>Corbett</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature10351</idno>
		<ptr target="https://doi.org/10.1038/nature10351" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">476</biblScope>
			<biblScope unit="page" from="298" to="303" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Analysis of the coding genome of diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Pasqualucci</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Trifonov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Fabbri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Rossi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Chiarenza</surname></persName>
		</author>
		<idno type="DOI">10.1038/ng.892</idno>
		<ptr target="https://doi.org/10.1038/ng.892" />
	</analytic>
	<monogr>
		<title level="j">Nat. Genet</title>
		<imprint>
			<biblScope unit="volume">43</biblScope>
			<biblScope unit="page" from="830" to="837" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The CREBBP acetyltransferase is a haploinsufficient tumor suppressor in B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Vlasevska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">A</forename><surname>Wells</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Nataraj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">B</forename><surname>Holmes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Duval</surname></persName>
		</author>
		<idno type="DOI">10.1158/2159-8290.CD-16-1417</idno>
		<ptr target="https://doi.org/10.1158/2159-8290.CD-16-1417" />
	</analytic>
	<monogr>
		<title level="j">Cancer Discov</title>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="page" from="322" to="337" />
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">The selection and function of cell type-specific enhancers</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Heinz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">E</forename><surname>Romanoski</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Benner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">K</forename><surname>Glass</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrm3949</idno>
		<ptr target="https://doi.org/10.1038/nrm3949" />
	</analytic>
	<monogr>
		<title level="j">Nat. Rev. Mol. Cell Biol</title>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="page" from="144" to="154" />
			<date type="published" when="2015" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">Super-enhancers in the control of cell identity and disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Hnisz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">J</forename><surname>Abraham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">I</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Lau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Saint-Andre</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Sigova</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.cell.2013.09.053</idno>
		<ptr target="https://doi.org/10.1016/j.cell.2013.09.053" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">155</biblScope>
			<biblScope unit="page" from="934" to="947" />
			<date type="published" when="2013" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">A</forename><surname>Alizadeh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">B</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><forename type="middle">S</forename><surname>Lossos</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<idno type="DOI">10.1038/35000501</idno>
		<ptr target="https://doi.org/10.1038/35000501" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">403</biblScope>
			<biblScope unit="page" from="503" to="511" />
			<date type="published" when="2000" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">J</forename><surname>Savage</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">L</forename><surname>Kutok</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Feuerhake</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Kurtin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Mihm</surname></persName>
		</author>
		<idno type="DOI">10.1182/blood-2004-07-2947</idno>
		<ptr target="https://doi.org/10.1182/blood-2004-07-2947" />
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">105</biblScope>
			<biblScope unit="page" from="1851" to="1861" />
			<date type="published" when="2005" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">Stromal gene signatures in large-B-cell lymphomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Dave</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Powell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Zhao</surname></persName>
		</author>
		<idno type="DOI">10.1056/NEJMoa0802885</idno>
		<ptr target="https://doi.org/10.1056/NEJMoa0802885" />
	</analytic>
	<monogr>
		<title level="j">N. Engl. J. Med</title>
		<imprint>
			<biblScope unit="volume">359</biblScope>
			<biblScope unit="page" from="2313" to="2323" />
			<date type="published" when="2008" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">N</forename><surname>Ngo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Lenz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><surname>Tolar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">P</forename><forename type="middle">B</forename><surname>Romesser</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature08638</idno>
		<ptr target="https://doi.org/10.1038/nature08638" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">463</biblScope>
			<biblScope unit="page" from="88" to="92" />
			<date type="published" when="2010" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Oncogenically active MYD88 mutations in human lymphoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">N</forename><surname>Ngo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">M</forename><surname>Young</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Schmitz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jhavar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Xiao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Lim</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature09671</idno>
		<ptr target="https://doi.org/10.1038/nature09671" />
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">470</biblScope>
			<biblScope unit="page" from="115" to="119" />
			<date type="published" when="2011" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">and CBP: partners for life and death</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Giordano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Avantaggiati</surname></persName>
		</author>
		<idno type="DOI">10.1002/(SICI)1097-4652(199911)181:2%3c218::AID-JCP4%3e3.0.CO;2-5</idno>
		<idno>218-230</idno>
		<ptr target="https://doi.org/10.1002/(SICI)1097-4652" />
	</analytic>
	<monogr>
		<title level="j">J. Cell. Physiol</title>
		<imprint>
			<biblScope unit="volume">181</biblScope>
			<biblScope unit="page">300</biblScope>
			<date type="published" when="1999" />
		</imprint>
	</monogr>
	<note>2%3c218::AID-JCP4%3e3.0.CO;2-5</note>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Conjunction dysfunction: CBP/p300 in human disease</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">H</forename><surname>Giles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><forename type="middle">J</forename><surname>Peters</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">H</forename><surname>Breuning</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0168-9525(98)01438-3</idno>
		<ptr target="https://doi.org/10.1016/S0168-9525(98" />
	</analytic>
	<monogr>
		<title level="j">Trends Genet</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="page" from="1438" to="1441" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">W</forename><surname>Gu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">G</forename><surname>Roeder</surname></persName>
		</author>
		<idno type="DOI">10.1016/S0092-8674(00)80521-8</idno>
		<ptr target="https://doi.org/10.1016/S0092-8674(00" />
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="page" from="80521" to="80529" />
			<date type="published" when="1997" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Stimulation of c-MYC transcriptional activity and acetylation by recruitment of the cofactor CBP</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Vervoorts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Luscher-Firzlaff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Rottmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><surname>Lilischkis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">G</forename><surname>Walsemann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Dohmann</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.embor.embor821</idno>
		<ptr target="https://doi.org/10.1038/sj.embor.embor821" />
	</analytic>
	<monogr>
		<title level="j">EMBO Rep</title>
		<imprint>
			<biblScope unit="volume">4</biblScope>
			<biblScope unit="page" from="484" to="490" />
			<date type="published" when="2003" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">Interferon regulatory factor 3 and CREB-binding protein/p300 are subunits of double-stranded RNA-activated transcription factor DRAF1</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">K</forename><surname>Weaver</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">P</forename><surname>Kumar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">N</forename><forename type="middle">C</forename><surname>Reich</surname></persName>
		</author>
		<idno type="DOI">10.1128/MCB.18.3.1359</idno>
		<ptr target="https://doi.org/10.1128/MCB.18.3.1359" />
	</analytic>
	<monogr>
		<title level="j">Mol. Cell. Biol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="page" from="1359" to="1368" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Mutations of CREBBP and SOCS1 are independent prognostic factors in diffuse large B cell lymphoma: mutational analysis of the SAKK 38/07 prospective clinical trial cohort</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Juskevicius</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Jucker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Klingbiel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Mamot</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Dirnhofer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Tzankov</surname></persName>
		</author>
		<idno type="DOI">10.1186/s13045-017-0438-7</idno>
		<ptr target="https://doi.org/10.1186/s13045-017-0438-7" />
	</analytic>
	<monogr>
		<title level="j">J. Hematol. Oncol</title>
		<imprint>
			<biblScope unit="volume">10</biblScope>
			<date type="published" when="2017" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">Somatic mutations of the CREBBP and EP300 genes affect response to histone deacetylase inhibition in malignant DLBCL clones</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">L</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Asmar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Klausen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Hasselbalch</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Gronbaek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia Res. Rep</title>
		<imprint>
			<biblScope unit="volume">2</biblScope>
			<biblScope unit="page" from="1" to="3" />
			<date type="published" when="2012" />
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
